Title :

The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis.

Author(s) :

Aussy, Audrey [Auteur]
Freret, Manuel [Auteur]
Gallay, Laure [Auteur]
Bessis, Didier [Auteur]
Vincent, Thierry [Auteur]
Jullien, Denis [Auteur]
Drouot, Laurent [Auteur]
Fabienne, Jouen [Auteur]
Joly, Pascal [Auteur]
Isabelle, Marie [Auteur]
Meyer, Alain [Auteur]
Sibilia, Jean [Auteur]
Bader-Meunier, Brigitte [Auteur]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Hamidou, Mohamed [Auteur]
Hue, Sophie [Auteur]
Charuel, Jean-Luc [Auteur]
Fabien, Nicole [Auteur]
Viailly, Pierre-Julien [Auteur]
Allenbach, Yves [Auteur]
Benveniste, Olivier [Auteur]
Cordel, Nadege [Auteur]
Boyer, Olivier [Auteur]

Journal title :

Arthritis & rheumatology (Hoboken, N.J.)

Abbreviated title :

null

Publication date :

2019-03-21

ISSN :

2326-5205

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: Anti-transcription intermediary factor 1γ (anti-TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti-TIF1γ-positive DM patients do not develop cancer. ...
Show more >OBJECTIVE: Anti-transcription intermediary factor 1γ (anti-TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti-TIF1γ-positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM. METHODS: This multicenter study was conducted in adult anti-TIF1γ-positive DM patients from August 2013 to August 2017. Anti-TIF1γ autoantibody levels and IgG subclasses were identified using a newly developed quantitative immunoassay. Age, sex, DM signs and activity, malignancy, and creatine kinase (CK) level were recorded. Risk factors were determined by univariate and multivariate analysis according to a Cox proportional hazards regression model. RESULTS: Among the 51 adult patients enrolled (mean ± SD age 61 ± 17 years; ratio of men to women 0.65), 40 (78%) had cancer and 21 (41%) died, with a mean ± SD survival time of 10 ± 6 months. Detection of anti-TIF1γ IgG2 was significantly associated with mortality (P = 0.0011) and occurrence of cancer during follow-up (P < 0.0001), with a 100% positive predictive value for cancer when the mean fluorescence intensity of anti-TIF1γ IgG2 was >385. None of the patients developed cancer after 24 months of follow-up. Univariate survival analyses showed that mortality was also associated with age >60 years (P = 0.0003), active DM (P = 0.0042), cancer (P = 0.0031), male sex (P = 0.011), and CK level >1,084 units/liter (P = 0.005). Multivariate analysis revealed that age >60 years (P = 0.015) and the presence of anti-TIF1γ IgG2 (P = 0.048) were independently associated with mortality. CONCLUSIONS: Our findings indicate that anti-TIF1γ IgG2 is a potential new biomarker of cancer that should be helpful in identifying the risk of mortality in anti-TIF1γ-positive DM patients.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2019-10-22T07:44:51Z